The United States just offically recliassified cannabis. The federal reclassification of medical …
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchTHCCBDIndustryDosingSafety Why This Matters Federal reclassification of cannabis from Schedule I to…
Virginia Lawmakers And Governor ‘Have A Deal’ On Bill To Legalize Marijuana Sales This Month
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyTHCDosingSafetyIndustryHempAnxiety Why This Matters Legalization of cannabis sales in Virginia will likely…
GLP-1 Drugs Compared: Semaglutide Vs Tirzepatide 2026
Tirzepatide dual GLP-1 GIP receptor agonist shows superior weight loss and glycemic control compared to semaglutide. This 2026 analysis highlights clinical distinctions important for prescribers. Understanding these differences aids personalized…
GLP-1 Receptor Agonist Tablet Approved for Weight Loss
The oral GLP-1 receptor agonist tablet offers a new, convenient option for weight loss treatment. This MHRA-approved formulation improves adherence compared to injectable forms. It represents a significant advancement in obesity management for family…
GLP-1 Receptor Agonist Evidence: Risks and Expert Guidance
GLP-1 receptor agonist dosing safety is critical for effective therapy and minimizing risks. This article reviews evidence and expert guidance on dosing strategies. Understanding dosing safety helps clinicians optimize patient outcomes with GLP-1…
Schedules of Controlled Substances: DEA Synthetic Cannabinoids Schedule I Placement 2026
The DEA synthetic cannabinoids schedule I placement 2026 marks a critical regulatory update for controlled substances. This action targets compounds like CUMYL-PEGACLONE due to high abuse potential. Clinicians must understand the clinical relevance of…
DEA Control of Synthetic Ketamine Analogs: 2-Fluorodeschloroketamine Scheduling
The DEA synthetic ketamine analog control includes the temporary Schedule I placement of 2-fluorodeschloroketamine (2-FDCK). This action addresses emerging synthetic drugs posing clinical and regulatory challenges. Clinicians should stay informed about…
Regulatory Update: Diphenidine Placement in Schedule I
The diphenidine regulatory scheduling update places this synthetic dissociative in Schedule I. This reflects concerns about its high abuse potential and no accepted medical use. Clinicians should monitor emerging patterns of diphenidine use amid evolving…
MOVii Certificate: complete guide to download it and receive subsidies. – YouTube
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchSafetyPolicyPainAnxietyMental HealthDosing Clinical Perspective I appreciate you sharing this, but the…
ASX Cannabis Stocks 2026: Why Proof Matters More Than Hype | Kalkine Media
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchIndustrySafetyDosingCBDTHC Why This Matters Cannabis companies’ financial viability and…